NZ524904A

NZ524904A - Association of the CB1 receptor antagonist and a sibutramine for treating obesity

Info

Publication number: NZ524904A
Application number: NZ524904A
Authority: NZ
Inventors: Odile Piot-Grosjean; Philippe Picaut; Francois Pititet
Original assignee: Aventis Pharma S
Priority date: 2000-10-04
Filing date: 2001-10-01
Publication date: 2004-11-26
Also published as: MXPA03002845A; NO20031521D0; SI1328269T1; KR20030036885A; CA2424934A1; DE60103556D1; YU26103A; HRP20030249A2; HUP0302044A2; PT1328269E; JP2004512279A; AU2001293936B2; FR2814678A1; EA200300441A1; DK1328269T5; BR0114410A; SI1328269T2; WO2002028346A2; WO2002028346A3; BG107739A

Abstract

A combination of a CB1 receptor antagonist and of sibutramine, its hydrate or one of its pharmaceutically acceptable salts. This combination is disclosed as being useful for treating obesity.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 524904 524904 ASSOCIATION OF THE CBl RECEPTOR ANTAGONIST AND A SIBUTRAMINE FOR TREATING OBESITY 5 The present invention relates to the combination of a CBl receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them, and to their use in the treatment of obesity. 10 CBl receptor antagonists are known for their effect on food intake and their use as anorexigenic (G. Colombo et al., Life Sciences, 63 (8), 113-117 (1998); J. Siamand et al., Behavioural Pharmacol., 9, 179-181 (1998)). 15 Sibutramine (BTS 54524; N-{1-[1-(4-chloro- phenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine; MeridiaR, ReductilR) , its hydrate and its pharmaceutical^ acceptable salts and in particular its hydrochloride reduces food intake and is of use in the 20 treatment of obesity (WO 90/061110; D.H. Ryan et al., Obesity Research, 3 (4), 553 (1995); H.C. Jackson et al., British Journal of Pharmacology, 121, 1758 (1997); G. Fanghanel et al., Inter. J. Obes., 24 (2), 144 (2000); G.A. Bray et al., Obes. Res., 7 (2), 189 25 (1999)) . It has now been found that the combination of sibutramine, its hydrate and its pharmaceutically acceptable salts and of a CBl receptor antagonist exhibits a synergistic effect in reducing food 30- consumption and is thus of use in the treatment of obesity. The combination can also comprise several CBl receptor antagonists. Use may in particular be made, among CBl 35 receptor antagonists, of the azetidine derivatives intellectual property office of n.z. 2 7 SEP ZOO't RECEIVED 2 disclosed in WO 00/15609, WO 01/64633 and WO 01/64634 of formula: a (i) 10 in which either R represents a chain (A) or (B) and / C=CH (A) R* so2r, or yf /SO2R, c ch N[ (B) ka Ri represents a methyl or ethyl radical, R2 represents either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being 15 unsubstituted or substituted by one or more halogen, alkyl, alkoxy, -CO-alk, hydroxyl, -COOR5, formyl, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitro, -NR6R7, -CO-NH-NR6R7, -N (alk) COOR8, cyano, -CONHRg, -CO-NRi6Ri7/ alkylsulfanyl, 20 hydroxyalkyl, -0-alk-NRi2Ri3 or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, indolinyl, indolyl, isochromanyl, isoquinolyl, pyridyl, 25 quinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,2,3,4-tetrahydroquinolyl, thiazolyl or thienyl rings, it being possible for these heteroaromatics to be 3 unsubstituted or substituted by a halogen, alkyl, alkoxy, -COOR5, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitro, -NR6R7, -CO-NH-NR6R7, cyano, -CONHRg, alkylsulfanyl, 5 hydroxyalkyl or alkylthioalkyl, R3 and R4, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl or indenyl, these aromatics being unsubstituted or 10 substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOR5, -CONRioRu r -CO-NH-NR6R7, alkylsulfanyl, hydroxyalkyl, -alk-NR6R7 or alkylthioalkyl, or a heteroaromatic chosen from the 15 benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydro-benzothienyl, furyl, isochromanyl, isoquinolyl, pyrrolyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl or thienyl rings, it being possible for these 20 heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOR5, -CO-NH-NR6R7, -CONRioRu, -alk-NR6R7, alkylsulfanyl, hydroxyalkyl or alkylthioalkyl, 25 R5 is an alkyl radical or a phenyl radical optionally substituted by one or more halogen atoms, R6 and R7, which are identical or different, represent a 30 hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R6 and R7 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring 35 members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being 4 substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, -CO-alk-NRi4Ri5, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, 5 R8 represents an alkyl radical, R9 represents a hydrogen atom or a radical of the type alkyl or alkyl substituted by dialkylamino, phenyl, cycloalkyl (optionally substituted by -COOalk) or a 10 saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals, 15 Rio and Ru, which are identical or different, represent a hydrogen atom or an alkyl radical or else Ri0 and Ru form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle 20 having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl radical, 25 R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl or cycloalkyl radical or else R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally 30 comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk or -CO-alk-NRi4Ri5 radical or a saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising 35 a heteroatom chosen from oxygen, sulfur and nitrogen, 5 R14 and R15, which are identical or different, represent a hydrogen atom or an alkyl or -COOalk radical, Ri6 and R17 form, together with the nitrogen atom to 5 which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen, 10 R' represents a hydrogen atom or a -CO-alk radical, or R represents a CHRis radical and Ris represents an -NHCOR19 or -N (R2o) -Y-R2i radical, 15 Y is CO or S02, R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and 20 indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, -COOalk, -CONR22R23, -CO-NH-NR24R25, alkylsulfanyl, alkylsulf inyl, 25 alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NH22R23, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, 30 pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, 35 alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25, -CONR22R23, -alk- 6 NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl, 5 Rig represents an -alk-S02-R26 radical, an -alk-S02~ CH=CH-R26 radical, a Heti radical substituted by -S02-R26 or a phenyl radical substituted by -SO2-R26 or -alk-S02-R26f 10 R20 represents a hydrogen atom or an alkyl radical, R21 represents a phenylalkyl, Heti or Ari radical, R22 and R23, which are identical or different, represent 15 a hydrogen atom or an alkyl radical or else R22 and R23 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and 20 nitrogen and optionally being substituted by one or more alkyl, R24 and R25, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, 25 alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R24 and R25 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen 30 from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2, 35 R26 represents an alkyl, Ari or Heti radical, 7 An represents a phenyl, naphthyl or indenyl radical, these radicals optionally being substituted by one or more halogen, alkyl, alkoxy, cyano, -CO-alk, -COOH, -COOalk, —CONR27R28f -CO-NH-NR29R30, alkylsulfanyl, 5 alkylsulfinyl, alkylsulfonyl, -alk-NR2gR3o, -NR29R30, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, Het, -O-alk-NH-cycloalkyl, OCF3, CF3, -NH-CO-alk, -S02NH2, -NH-COCH3, -NH-COOalk or Het or else on 2 adjacent carbon atoms by dioxymethylene, 10 Heti represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen which is optionally substituted by 15 one or more alkyl, alkoxy, vinyl, halogen, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3, the nitrogenous heterocycles optionally being in their N-oxidized form, 20 R27 and R28, which are identical or different, represent a hydrogen atom or an alkyl radical or else R27 and R28 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising 25 another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals, R29 and R30, which are identical or different, represent 30 a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R29 and R3o form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring 35 members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being 8 substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, 5 or R represents CHR31 and R31 represents an -N(R32)R33, -N (R32)-CO-R33 or -N (R32) -S02R34 radical, 10 R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, 15 -CO-alk, cyano, -COOH, COOalk, -CONR22R23, -CO-NH-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7Rs^ or a heteroaromatic chosen from the benzofuryl, 20 benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetra-hydroisoquinolyl, thiazolyl and thienyl rings, it being 25 possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25, -CONR22R23, -alk-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, 30 alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl, R32 represents a -C (R35) (R36)-Het2, -Het2, -C (R35) (R36)-Ar2, Ar2, cycloalkyl or norbornyl radical, 9 10 15 20 R.33 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen, R34 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen, R35 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxyalkyl, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally substituted by one or more halogen, R36 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxyalkyl or alkyl radical, the latter optionally substituted by one or more halogen, or else R35 and R36 form, together with the carbon atom to which they are attached, a saturated mono- or bicyclic ring having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, 25 sulfur and nitrogen and optionally being substituted by one or more alkyl, Ar2 represents a phenyl, naphthyl or indenyl radical, these various radicals optionally being substituted by 30 one or more halogen, alkyl, alkoxy, -CO-alk, cyano, -COOH, -COOalk, -CONR37R38, -CO-NH-R39R40, alkylsulfanyl, alkylsulf inyl, alkylsulfonyl, -alk-NR39R4o, -NR39R40, alkylthioalkyl, formyl, CF3, OCF3, Het, -O-alk-NH-cycloalkyl, S02NH2, hydroxyl, hydroxyalkyl, -NHCOalk or 35 NHCOOalk or on 2 adjacent carbon atoms by dioxymethylene, 10 Het2 represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, 5 sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, halogen, alkoxycarbonyl, oxo or hydroxyl, the nitrogenous heterocycles optionally being in their N-oxidized form, 10 R37 and R38, which are identical or different, represent a hydrogen atom or an alkyl radical or else R37 and R38 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising 15 another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, R39 and R40, which are identical or different, represent 20 a hydrogen atom or an alkyl radical or else R39 and R40 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and 25 nitrogen and optionally being substituted by one or more alkyl, alk represents an alkyl or alkylene radical, 30 the alkyl and alkylene radicals and portions and the alkoxy radicals and portions have straight or branched chains and comprise 1 to 6 carbon atoms and the cycloalkyl radicals comprise 3 to 10 carbon atoms, 11 the optical isomers of these compounds and their pharmaceutically acceptable salts with an inorganic or organic acid. The preferred azetidine derivatives are as 5 follows: l-benzhydryl-3-[(methylsulfonyl)(phenyl)-methylene]azetidine, l-benzhydryl-3-[(3-methylphenyl)(methylsulfonyl)-methylene]azetidine, 10 l-benzhydryl-3-[(3-chlorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3,5-dichlorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(2,5-dichlorophenyl)(methylsulfonyl)-15 methylene]azetidine, l-benzhydryl-3-[(2,3-dichlorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-fluorophenyl)(methylsulfonyl)-methylene]azetidine, 20 l-benzhydryl-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-bromophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-iodophenyl)(methylsulfonyl)-25 methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-methoxyphenyl)methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-methylphenyl)methylene]azetidine, 30 l-benzhydryl-3-{[3,5-bis(trifluoromethyl)phenyl]-(methylsulfonyl)methylene}azetidine, l-benzhydryl-3-[(3,5-dibromophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-methoxycarbonylphenyl)-35 (methylsulfonyl)methylene]azetidine, 12 l-benzhydryl-3-[(3-cyanophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-carbamoylphenyl)(methylsulfonyl)-methylene]azetidine, 5 l-benzhydryl-3-[(methylsulfonyl) (naphth-l-yl) (methylsulfonyl) methylene] azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(4-methoxyphenyl)methyl]-3-[(3,5-difluoro-10 phenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(4-methylphenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, (RS)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-l-[(4-methoxyphenyl)(phenyl)methyl)]azetidine, 15 (R)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-l-[(4-methoxyphenyl)(phenyl)methyl]azetidine, (S)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-1-[(4-methoxyphenyl)(phenyl)methyl]azetidine, 1-[bis(4-trifluoromethoxyphenyl)methyl]-3-[(3,5-di-20 fluorophenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-trifluoromethylphenyl)methyl]-3-[(3, 5-di-fluorophenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{ [3,5-bis(trifluoromethyl )phenyl]methylsulfonylmethylene}azetidine, 25 (RS)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[ (3,5-difluorophenyl) (methylsulfonyl)-methylene]azetidine, (R)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[ (3,5-difluorophenyl) (methylsulfonyl)-30 methylene]azetidine, (S)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[ (3,5-difluorophenyl) (methylsulfonyl)-methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4-35 (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 13 (R)—1—{(4-chlorophenyl) [4- (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (S)—1—{ (4-chlorophenyl) [4-5 (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4- (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 10 (R)-l-{(4-chlorophenyl)[4- (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (S)—1—{(4-chlorophenyl)[4- (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-15 phenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl )(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-20 ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{ (S)-(4-chlorophenyl) [4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl )(methylsulfonyl)methylene]azetidine, 25 l-{(RS)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-30 phenyl)(methylsulfonyl)methylene]azetidine, l-{ (S)-(4-chlorophenyl) [4-(thiomorpholin-4-ylmthyl)phenyl]methyl}-3-[(3,5-difluorophenyl )(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(N-ethyl-N-35 cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 14 l-{(R)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 1~{(S)-(4-chlorophenyl)[4-(N-ethyl-N-5 cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, 1-{{ (RS)-(4-chlorophenyl) {4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 10 1-{{ (R) -(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, l-{{(S)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}—3—[(3,5— 15 difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[ 4-(N-cyclopropyl-N-20 propylaminomethyl)phenyl]methyl}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{ (S)- (4-chlorophenyl) [4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 25 l-{ (RS)-(4-chlorophenyl) [4-(diisopropylamino-methyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-30 sulfonyl)methylene]azetidine, l-{ (S)- (4-chlorophenyl) [4-(diisopropylaminomethyl)-phenyl]methyl}-3-[(3, 5-difluorophenyl) (methylsulfonyl)-methylene]azetidine, 1-{{ (RS)- (4-chlorophenyl) {4-[bis(2-methoxyethyl)-35 aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 15 1-{{(R)~(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1~{{ (S)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-5 aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-{(RS)-(4-chlorophenyl)[4-[di-n- propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 10 l-{(R)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)- phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-15 sulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl) methylene] azetidine, l-{(R)-(4-chlorophenyl)[4-(piperidin-l-ylmethyl)-20 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{ (S)-(4-chlorophenyl) [4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, 25 1-{(RS)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-30 (methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(morpholin-4-35 ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 16 l-{(R)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-phenyl]methyl}-3-[ (3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-5 phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, 10 l-{(R)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{(S)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-15 sulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[ 4-(piperazin-2-one-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl sulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl) 20 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{(S)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl) phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, 25 l-{(RS)-(4-chlorophenyl)[4-(imidazol-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{(R)-(4-chlorophenyl)[4-(imidazol-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-30 sulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(imidazol-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, (RS)-1-{(4-chlorophenyl)[4-(N,N-35 dimethylcarbamoyl)phenyl]methyl}-3-[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 17 (R)—1—{(4-chlorophenyl)[4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)—1—{(4-chlorophenyl) [4-(N,N-5 dimethylcarbamoyl)phenyl]methyl}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-1-{(4-chlorophenyl)[4-(N-ethylcarbamoyl)phenyl]methyl)}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 10 (R) —1— { (4-chlorophenyl) [4-(fief hyl carbamoyl) phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)—1—{(4-chlorophenyl) [4-(N-ethylcarbamoyl)phenyl]methyl}-3-[(3,5— 15 difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3 [ (3,5-difluorophenyl) (methylsulfonyl)methylene]-azetidine, (R)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-20 [(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine, (S)—1—[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine, 25 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-dichloro-phenyl)(methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(3-methylsulfanylphenyl)(methylsulfonyl) methylene]azetidine, l-benzhydryl-3-[(3-methylsulfanylmethyl)phenyl)]-30 (methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-cyanophenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-carbamoylphenyl) (methylsulfonyl)methylene]azetidine, 35 1-[bis(4-chlorophenyl)methyl]-3-[(3-methoxyphenyl)-(methylsulfonyl)methylene]azetidine, 18 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxyphenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-pyrrolidinylphenyl)methylene]azetidine, 5 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxy- methylphenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{(methylsulfonyl)[3-(N-piperidylcarbamoyl)phenyl]methylene}azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-10 trifluoromethylsulfanylphenyl)(methylsulfonyl)-methylene]azetidine, 1-[bis(4-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(2-fluorophenyl)methyl]-3-[(3,5-difluorophenyl) -15 (methylsulfonyl)methylene]azetidine, 1-[bis(3 — fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, 20 (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl) (thien-2-yl)methyl]-3-[(3,5-25 difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 30 l-benzhydryl-3-[(ethylsulfonyl)(phenyl)methylene]-azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{{3-[N-(4-methylpiperazinyl)carbamoyl]phenyl}(methylsulfonyl)-methylene}azetidine, 19 1-[bis(4-chlorophenyl)methyl]-3-{[3—(2,2— dimethylcarbohydrazido)phenyl](methylsulfonyl)-methylene}azetidine, 1-[bis(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)-5 (methylsulfonyl)methylene]azetidine, 1-[bis(p-tolyl)methyl]-3-[(methylsulfonyl)-(phenyl)methylene]azetidine, l-[ (4-chlorophenyl) (4-hydroxymethylphenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-10 azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-methylaminophenyl) (methylsulfonyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]—3—[<3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 15 (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(2-20 methoxycarbonylthien-5-yl)methylene]azetidine, (RS)-1-[bis(4-chlorophenyl)methyl]-3-hydroxy-3-[(methylsulfonyl)(2-methoxycarbonylthien-5-yl)methyl]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(2-isobutylamino-25 carbonylthien-5-yl)(methylsulfonyl)methylene]azetidine 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3-methoxy-carbonylphenyl)(methylsulfonyl)methyl]azetidin-3-ol, 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(methylsulfonyl) (pyridin-4-yl)methyl]azetidin-3-ol, 30 1-[bis(4-chlorophenyl)methyl]-3-[(RS)- (methylsulfonyl)(pyridin-3-yl)methyl]azetidin-3-ol, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(morpholin-4-yl)propyl)benzamide, 20 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-dimethylaminopropyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-5 ylidene}(methanesulfonyl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)benzamide, 3—({1—[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-dimethylamino-l methylethyl)benzamide, 10 3-({l-[bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)-N-(piperidin-1-yl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-isobutylbenzamide, 15 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)-N-(3-(imidazol-1-yl)propyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-20 dimethylaminoethyl)benzamide, N'-methylhydrazide of 3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)-methyl)benzoic acid, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-25 ylidene}(methanesulfonyl)methyl)-N-(2-(morpholin-4-yl)ethyl)benzamide, 3—({1—[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(1-ethylpyrrolidin 2-ylmethyl)benzamide, 30 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2,2-dimethylpropyl)benzamide, 3 - ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-35 (cyclohexylmethyl)benzamide, 21 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(cyclopropylmethyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-5 ylidene}(methanesulfonyl)methyl)-N-(2-methylbutyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-phenylpropyl)benzamide, 10 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)-N-(tetrahydrofuran-2-ylmethyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2, 2-15 diphenylethyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-ethylbutyl)benzamide, methyl ester of 4-{[3-({1-[bis(4-chlorophenyl)methyl]-20 azetidin-3-ylidene}(methanesulfonyl)methyl)- benzoylamino]methyl}cyclohexanecarboxylic acid, 2-amino-1-{4-[3-({l-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazin-l-ylJethanone, 25 tert-butyl ester of (2-{4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazin-l-yl}-2-oxoethyl)carbamic acid, 1-{4-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl}- 30 2-(methylamino)ethanone, tert-butyl ester of (2-{4-[3-({1-[bis (4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl}- 2-oxoethyl)-N-methylcarbamic acid, 22 N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-l-carbothioic acid, N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)methyl]-5 azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazine-l-carboxylic acid, methyl ester of 4-[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-l-carboxylic acid, 10 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-isobutylpiperazine, 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-15 ethylpiperazine, 4-acetyl-l-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine, l-{4-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl}-20 2-dimethylaminoethanone, 1- [3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine, tert-butyl ester of 4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-25 phenyl]piperazine-l-carboxylic acid, 1-[bis(4-methoxycarbonylphenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 3-acetoxy-l-[bis(4-methoxycarbonylphenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylsulfonyl)methyl]- 30 azetidine, (RS)-4-[4-((4-chlorophenyl) {3 - [ (3,5- difluorophenyl)(methanesulfonyl)methylene]azetidin-1-yl}methyl)benzyl]morpholine, 4-(4-{3-[(l-benzhydrylazetidin-3-ylidene)(methane-35 sulfonyl)methyl]phenoxy}butyl)morpholine, 23 4-(4-{3-[(l-benzhydrylazetidin-3-ylidene)(methanesulfonyl) methyl]phenoxy}propyl)morpholine, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}thien- 2-ylsulfonamide, 5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide, N-[4-(N—{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-sulfamoyl)phenyl]acetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 4-methylphenylsulfonamide, N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dimethoxyphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3-fluorophenylsulfonamide, 15 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dichlorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-cyanophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-20 2,5-dimethoxyphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-trifluoromethylphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-2 ylsulfonamide, 25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-l ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-difluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-30 1-methyl-lH-imidazol-4-ylsulfonamide, N-[4-(N-{l-[bis(4-chlorophenyl)methyl]azetidin- 3-yl}sulfamoyl)-2-chlorophenyl]acetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid- 3-ylsulfonamide, 35 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 4-fluorophenylsulfonamide, 24 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulfonamide, 5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(phenylmethyl)sulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,5-difluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-10 2-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-(3-fluoro-5-pyrrolidin-l-ylphenyl)sulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4-fluorophenylsulfonamide, 15 N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylquinol-8-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylphenylsulfonamide, N- {1- [bis (4-chlorophenyl)methyl]azetidin-3-yl}-20 N-methyl(phenylmethyl)sulfonamide, N-{1-[bis (4-chlorophenyl)methyl]azetidin-3-yl}- 3-sulfamoylphenylsulfonamide, 2-benzenesulfonyl-N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}acetamide, 25 N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2-(4-toluene-4-sulfonyl)acetamide, (3-chloro-4-(methylsulfonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]amide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-30 3-(2-phenylethylenesulfonyl)propionamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 4-(methylsulfonyl)benzamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-(methanesulfonyl)benzamide, 35 (5-(methylsulfonyl)thiophene-2-carboxy)- {1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide, 25 (5-methylsulfonyl-3-methyl-4-vinylthiophene- 2-carboxy){1-[bis(4-chlorophenyl)methyl]azetidin- 3-yl}amide, (RS)-N-{1-[(4-chlorophenyl)(pyridin-3-yl)methyl]-5 azetidin-3-yl}-3,5-difluorobenzenesulfonamide, (RS)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-chloropyrid-2-yl)methylsulfonamide, 10 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-ethylpyrid-2-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(quinol-6-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-15 N-(quinol-5-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(isoquinol-5-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide, 20 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-l-oxide-3-yl)methylsulfonamide, N-(1R,2S,4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-(4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide, N-(1R,2R,4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-25 (4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(thiazol-2-yl)methylsulfonamide, 30 N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-methoxyphenyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-hydroxyphenyl)methylsulfonamide, N-{1-[bis (4-chlorophenyl)methyl]azetidin-3-yl}-35 N-(3-(hydroxymethyl)phenyl)methylsulfonamide, 26 ethyl N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(methylsulfonyl)-3-aminobenzoate, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(isobutylpiperid-4-yl)methylsulfonamide, 5 N-benzyl-N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-ylJamine, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)amine, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 N-(3,5-difluorobenzyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-ylmethyl)methylsulfonamide, N-{1-[bis(4-fluorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, 15 (RS)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (R)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (S)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-20 3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (RS)-N-{l-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (R)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3, 5-difluorophenyl)methylsulfonamide, 25 (S)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (RS)-N-{l-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (R)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-30 azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (S)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)benzylsulfonamide, 35 their optical isomers and their pharmaceutically acceptable salts with an inorganic or organic acid. 27 And even more particularly preferred are the following azetidine derivatives: 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3,5-difluorophenyl) (methylsulfonyl)methyl]azetidin-3-ol, 5 3-acetoxy-l-[bis(4-chlorophenyl)methyl]-3-[(RS)- (3,5-difluorophenyl)(methylulphonyl)methyl)methylsulfon ylmethyl]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 10 their optical isomers and their pharmaceutically acceptable salts with an inorganic or organic acid. pharmaceutically acceptable salts of the azetidine derivatives, of the following salts: benzenesulfonate, 15 hydrobromide, hydrochloride, citrate, ethanesulfonate, fumarate, gluconate, iodate, isethionate, maleate, methanesulfonate, methylenebis-p-oxynaphthoate, nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulfate, tartrate, theophyllinacetate and p-20 toluenesulfonate. combinations according to the invention are, for example, the pyrazole derivatives disclosed in EP 576 357, EP 658 546, EP 656 354, WO 97/19063 and 25 WO 00/46209, the benzothiophene and benzofuran derivatives disclosed in WO 96/02248 or the arylsulfonamides disclosed in WO 98/37061. Mention may in particular be made of the products known under the code SR141716 and LY320135. 30 The synergistic effect of the combination of sibutramine and of a CBl receptor antagonist on food intake was determined according to the following protocol: 35 originating from Iffa-Credo, France, were used in this study. The rats are housed in individual cages and Mention may be made, as examples of -Other- G&l receptor - of use in the Obese Fa/fa Zucker rats aged 7 weeks and intellectual prope office of n.z. RECEIVE 0 3 aug 20m 28 weighed every day between 8 and 10 o'clock in the morning. The amount of food is also weighed each morning at the same time. This food (M20, Pietrement, France) is changed every day and the rats have free 5 access thereto for 24 hours. All the rats are treated for a week with the vehicle (miglyol 812N and 0.5% methylcellulose/O.2% polysorbate 80) in two consecutive administrations. The rats are treated from the 8th day with the vehicle, the CBl receptor antagonist (1-10 [bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine) or sibutramine by the oral route (see table below). The sibutramine is dissolved in a 0.5% methylcellulose/O.2% polysorbate 80 solution and 15 administered at a dose of 3 mg/kg; the CBl [lacuna] antagonist is dissolved in miglyol 812N (Huls, Germany) at a dose of 0.6 mg/kg and the two products are administered under a volume of 1 ml/kg. Each group is composed of 12 to 14 animals. The following groups are 20 formed and the animals are treated for five days at the rate of two -consecutive administrations every day. GROUP First administration Second admini s tration 1 "vehicle group" miglyol 0.5% methylcellulose/ 0.2% polysorbate 2 "sibutramine group" miglyol sibutramine 3 mg/kg 3 ■"CBl receptor antagonist group" CBl receptor antagonist 0.6 mg/kg 0.5% methylcellulose/ 0.2% polysorbate 4 "combination group" CBl receptor antagonist 0.6 mg/kg sibutramine 3 mg/kg I w'VJc OF M.7. j sep : 29 The food consumption of each animal is measured every day. The results are expressed as mean amount of food consumed during the 5 days of treatment. 5 The results obtained are given in the table below. Treatment Food consumption during the 5 days of treatment (g) Vehicles 25.52 ± 0.30 sibutramine 3 mg/kg 24.60 ± 0.32* CBl receptor antagonist 0.6 mg/kg 24.00 ± 0.24** sibutramine (3 mg/kg) + CBl receptor antagonist (0.6 mg/kg) 22.76 ± 0.02*** *p<0.05 **p<0.01 ***p<0.0001 The results show that, in the animals 10 receiving the sibutramine and CBl receptor antagonist combination, the reduction in food c oris ump t'ion T s much greater has that of the animals treated either with sibutramine alone or with the CBl receptor antagonist alone. 15 The compounds of the combination can be employed orally, parenterally, transdermally or rectally, either simultaneously or separately or spread out over time. The present invention also relates to the 20 pharmaceutical compositions comprising the combination of sibutramine, its hydrate or one of its pharmaceutically acceptable salts and of a CBl receptor antagonist in the pure state or with one or more compatible and pharmacologically acceptable diluents 25 and/or adjuvants and/or optionally in combination with another pharmaceutically compatible aridphysiologically i ::'^al : "■ ,;yy" J * -OF N.Z. I _ y cr:o P. ~ n - a ^ ^ 30 active product for a use which is either simultaneous or separate or spread out over time. Use may be made, as solid compositions for oral administration, of tablets, pills, powders (hard 5 gelatin capsules, cachets) or granules. In these compositions, the active principles are mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under an argon stream. These compositions can also comprise substances other 10 than the diluents, for example one or more lubricants such as magnesium stearate or talc, a colorant, a coating (dragees) or a glaze. Use may be made, as liquid compositions for oral administration, of pharmaceutically acceptable 15 solutions, suspensions, emulsions, syrups and elixirs comprising inert diluents, such as water, ethanol, glycerol, vegetable oils or liquid paraffin. These compositions can comprise substances other than the diluents, for example wetting, sweetening, thickening, 20 flavouring or stabilizing products. The sterile compositions for parenteral administration can preferably be solutions in aqueous or nonaqueous form, suspensions or emulsions. Use may be made, as solvent or vehicle, of water, propylene 25 glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents. These compositions can also comprise adjuvants, in particular wetting, isotonizing, 30 emulsifying, dispersing and stabilizing agents. Sterilization can be carried out in several ways, for example by aseptic filtration, by incorporating sterilizing agents in the composition, by irradiation or by heating. They can also be prepared in the form of 35 sterile solid compositions which can be dissolved at </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 31 the time of use in sterile water or any other injectable sterile medium. The compositions for rectal administration are suppositories or rectal capsules which comprise, in .5 addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols. The pharmaceutical compositions generally comprise 0.5 to 10 mg of sibutramine and 0.1 to 200 mg 10 of the CBl receptor antagonist. The present invention also relates to the method , for the treatment of obesity which consists in administering, to the patient, a combination according to the invention either simultaneously or separately or 15 spread out over time. the doses depend on the desired effect, on the duration of treatment and on the administration route used; they are generally from 1 to 15 mg of sibutramine per day by the oral route for an adult and 20 from 0.10 to 500 mg of the CBl receptor antagonist per day by the oral route for an adalt; Generally, the doctor will determine the appropriate dosage according to the age, weight and any other factor specific to the subject to be treated. intellectual property office of n.z 0 3 aug 2004 RECEIVED 32 CLAIMS

1. A combination of a CBl receptor antagonist and of sibutramine, its hydrate or one of its pharmaceutically acceptable salts.

2. The combination as claimed in claim 1, for which the CBl receptor antagonist is a compound of formula: 10 (I) in which either R represents a chain (A) or (B) and 15 :CH \. (A) or f /scyi, C CH (B) 'R Ri represents a methyl or ethyl radical, R2 represents either an aromatic chosen from phenyl, 20 naphthyl or indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, -CO-alk, hydroxyl, -COOR5, formyl, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitro, -NR6R7, -CO-NH-NR6R7, 25 -N(alk)COOR8, cyano, -CONHRg, -CO-NRi6R17, alkylsulfanyl, hydroxyalkyl, -0-alk-NRi2Ri3 or alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, intellectual property office of n.z. 0 3 aug 2004 RECEIVED 33 benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, indolinyl, indolyl, isochromanyl, isoquinolyl, pyridyl, quinolyl, 1,2,3, 4-tetrahydroisoquinolyl, 5 1,2,3,4-tetrahydroquinolyl, thiazolyl or thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, -COOR5, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy, nitro, 10 -NR6R7, -CO-NH-NR6R7, cyano, -CONHRg, alkylsulfanyl, hydroxyalkyl or alkylthioalkyl, R3 and R4, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl or 15 indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOR5, -CONRxoRn, -CO-NH-NR6R7, alkylsulfanyl, hydroxyalkyl, -alk-NR6R7 or 20 alkylthioalkyl, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, isochromanyl, isoquinolyl, pyrrolyl, quinolyl, 1,2,3, 4-tetrahydroisoquinolyl, thiazolyl or 25 thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOR5, -CO-NH-NR6R7, -CONRioRu, -alk-NR6R7, alkylsulfanyl, hydroxyalkyl or 30 alkylthioalkyl, R5 is an alkyl radical or a phenyl radical optionally substituted by one or more halogen atoms, 35 Rg and R7, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, 34 alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R.6 and R7 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring 5 members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, -CO-alk-NRi4Ris, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, 10 Rs represents an alkyl radical, Rg represents a hydrogen atom or a radical of the type alkyl or alkyl substituted by dialkylamino, phenyl, 15 cycloalkyl (optionally substituted by -COOalk) or a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen and optionally being substituted by 20 one or more alkyl radicals, Rio and Ru, which are identical or different, represent a hydrogen atom or an alkyl radical or else Rio and Ru form, together with the nitrogen atom to which they are 25 attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by an alkyl radical, 30 R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl or cycloalkyl radical or else R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic 35 heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, 35 sulfur and nitrogen and optionally being substituted by an alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk or -CO-alk-NRi4Ri5 radical or a saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising 5 a heteroatom chosen from oxygen, sulfur and nitrogen, Ri4 and Ri5, which are identical or different, represent a hydrogen atom or an alkyl or -COOalk radical, 10 R16 and R17 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen, 15 R' represents a hydrogen atom or a -CO-alk radical, or R represents a CHRie radical and 20 Ris represents an -NHCOR19 or -N (R2o)-Y-R2i radical, Y is CO or SO2, R4 and R3, which are identical or different, represent 25 either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, -COOalk, -CONR22R23A 30 -CO-NH-NR24R25, alkylsulfanyl, alkylsulf inyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NH22R23, or a heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 35 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, 36 isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, 5 alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25, -CONR22R23/ -alk-NR24R25, alkylsulfanyl, alkylsulf inyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl, 10 R19 represents an -alk-S02-R26 radical, an -alk-S02-CH=CH-R26 radical, a Heti radical substituted by -SO2-R26 or a phenyl radical substituted by -S02-R26 or -alk-S02-R26 ? 15 R2o represents a hydrogen atom or an alkyl radical, R21 represents a phenylalkyl, Heti or Ari radical, 20 R22 and R23, which are identical or different, represent a hydrogen atom or an alkyl radical or else R22 and R23 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising 25 another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, R24 and R25, which are identical or different, represent 30 a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R24 and R25 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring 35 members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being 37 substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2, 5 R26 represents an alkyl, Arx or Heti radical, Ari represents a phenyl, naphthyl or indenyl radical, these radicals optionally being substituted by one or more halogen, alkyl, alkoxy, cyano, -CO-alk, -COOH, 10 -COOalk, -CONR27R28, -CO-NH-NR29R30, alkylsulfanyl, alkylsulf inyl, alkylsulfonyl, -alk-NR29R30, -NR29R30, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, Het, -O-alk-NH-cycloalkyl, OCF3, CF3, -NH-CO-alk, -S02NH2, -NH-COCH3, -NH-COOalk or Het or else on 2 adjacent 15 carbon atoms by dioxymethylene, Heti represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, 20 sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, vinyl, halogen, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3, the nitrogenous heterocycles optionally being in their N-oxidized form, 25 R27 and R28, which are identical or different, represent a hydrogen atom or an alkyl radical or else R27 and R28 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle 30 having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl radicals, 35 R29 and R30, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, 38 10 15 alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R29 and R30 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, or R represents CHR31 and R3i represents an -N(R32)R33, -N (R32)-CO-R33 or -N (R32)-SO2R34 radical, R4 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted by one of more halogen, alkyl, alkoxy, 20 formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano, -COOH, COOalk, -CONR22R23r -CO-NH-NR24R25, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7R8, or a 25 heteroaromatic chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetra-30 hydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR24R25, -CONR22R23/ -alk-NR24R25/ 35 alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, 39 alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl, R32 represents a -C (R35) (R36)-Het2, -Het2, -C (R35) (R36)-Ar2, 5 Ar2, cycloalkyl or norbornyl radical, R33 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter 10 optionally substituted by one or more halogen, R34 represents a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxy, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter optionally 15 substituted by one or more halogen, R35 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23, alkoxyalkyl, Ar2, Het2, -CH2Ar2, -CH2Het2 or alkyl radical, the latter 20 optionally substituted by one or more halogen, R36 represents a hydrogen atom or a hydroxyalkyl, -alk-COOalk, -alk-CONR22R23, -alk-NR22R23/ alkoxyalkyl or alkyl radical, the latter optionally substituted by one 25 or more halogen, or else R35 and R36 form, together with the carbon atom to which they are attached, a saturated mono- or bicyclic ring having 3 to 10 ring members optionally 30 comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, 35 Ar2 represents a phenyl, naphthyl or indenyl radical, these various radicals optionally being substituted by one or more halogen, alkyl, alkoxy, -CO-alk, cyano, 40 -COOH, -COOalk, -CONR37R38, -CO-NH-R39R40, alkylsulfanyl, alkylsulf inyl, alkylsulfonyl, -alk-NR39R4o, -NR39R40/ alkylthioalkyl, formyl, CF3, OCF3, Het, -O-alk-NH-cycloalkyl, SO2NH2, hydroxyl, hydroxyalkyl, -NHCOalk or 5 NHCOOalk or on 2 adjacent carbon atoms by dioxymethylene, Het2 represents an unsaturated or saturated mono- or bicyclic heterocycle having 3 to 10 ring members and 10 comprising one or more heteroatoms chosen from oxygen, sulfur and nitrogen which is optionally substituted by one or more alkyl, alkoxy, halogen, alkoxycarbonyl, oxo or hydroxyl, the nitrogenous heterocycles optionally being in their N-oxidized form, 15 R37 and R38f which are identical or different, represent a hydrogen atom or an alkyl radical or else R37 and R38 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle 20 having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, 25 R39 and R4o, which are identical or different, represent a hydrogen atom or an alkyl radical or else R39 and R40 form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising 30 another heteroatom chosen from oxygen, sulfur and nitrogen and optionally being substituted by one or more alkyl, alk represents an alkyl or alkylene radical, 41 the alkyl and alkylene radicals and portions and the alkoxy radicals and portions have straight or branched chains and comprise 1 to 6 carbon atoms and the cycloalkyl radicals comprise 3 to 10 carbon atoms, 5 the optical isomers of these compounds and their pharmaceutically acceptable salts with an inorganic or organic acid.

3. The combination as claimed in claim 2, 10 for which the compound of formula (I) is chosen from the following compounds: l-benzhydryl-3-[(methylsulfonyl)(phenyl)-methylene]azetidine, l-benzhydryl-3-[(3-methylphenyl)(methylsulfonyl)-15 methylene]azetidine, l-benzhydryl-3-[(3-chlorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3,5-dichlorophenyl)(methylsulfonyl)-methylene]azetidine, 20 l-benzhydryl-3-[(2,5-dichlorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(2,3-dichlorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-fluorophenyl)(methylsulfonyl)-25 methylene]azetidine, l-benzhydryl-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-bromophenyl)(methylsulfonyl)-methylene]azetidine, 30 l-benzhydryl-3-[(3-iodophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-methoxyphenyl)methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl)(3-trifluoro-35 methylphenyl)methylene]azetidine, 42 l-benzhydryl-3-{[3,5-bis(trifluoromethyl)phenyl]-(methylsulfonyl)methylene}azetidine, l-benzhydryl-3-[(3,5-dibromophenyl)(methylsulfonyl)-methylene]azetidine, 5 l-benzhydryl-3-[(3-methoxycarbonylphenyl)-(methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(3-cyanophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-carbamoylphenyl)(methylsulfonyl)-10 methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl)(naphth-l-yl)(methylsulfonyl) methylene] azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, 15 1-[bis(4-methoxyphenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(4-methylphenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (RS)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene 20 1-[(4-methoxyphenyl)(phenyl)methyl)]azetidine, (R)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene] l-[(4-methoxyphenyl)(phenyl)methyl]azetidine, (S)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene] l-[(4-methoxyphenyl)(phenyl)methyl]azetidine, 25 1-[bis(4-trifluoromethoxyphenyl)methyl]-3-[(3, 5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(4-trifluoromethylphenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{ [3,5-bis(trifluoro-30 methyl)phenyl]methylsulfonylmethylene}azetidine, (RS)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3 [(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, (R)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-35 [(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, 43 (S)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4-5 (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (R)—1—{(4-chlorophenyl) [4- (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 10 (S)-l-{ (4-chlorophenyl) [4- (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4- (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-15 phenyl)(methylsulfonyl)methylene]azetidine, (R)—1—{(4-chlorophenyl)[4- (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (S)—1—{(4-chlorophenyl) [4-20 (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl )(methylsulfonyl)methylene]azetidine, l-{ (RS) - (4-chlorophenyl) [.4-(3, 3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 25 l-{(R)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{ (S)-(4-chlorophenyl) [4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-30 phenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(thiomorpholin-4-35 ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 44 l-{ (S)- (4-chlorophenyl) [4-(thiomorpholin-4-ylmthyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(N-ethyl-N-5 cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 10 l-{ (S)- (4-chlorophenyl) [4-(N-ethyl-N- cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 1-{{(RS)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-15 difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{{(R)~(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[ (3, 5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 1-{{(S)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-20 piperazinyl)methyl]phenyl}methyl}}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{ (RS)-(4-chlorophenyl) [4 -(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 25 1-{(R)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-30 difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(diisopropylaminomethyl) phenyl] methyl } -3- [(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-35 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, 45 l-{(S)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, l-{{(RS)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-5 aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-{{(R)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 10 1-{{(S)-(4-chlorophenyl){4-[bis(2-methoxyethyl)- aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-{(RS)-(4-chlorophenyl)[4-[di-n- propylaminomethyl) phenyl]methyl}-3-[(3,5-difluoro-15 phenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, l-{ (S)-(4-chlorophenyl) [4-(di-n-propylaminomethyl)-20 phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl )methylene]azetidine, 1-{(RS)-(4-chlorophenyl)[4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl )methylene]azetidine, 25 l-{(R)-(4-chlorophenyl)[4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl )methylene]azetidine, l-{ (S)-(4-chlorophenyl) [4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-30 sulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(4-methylpiperazin-l-35 ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 46 l-{ (S)- (4-chlorophenyl) [4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(morpholin-4-5 ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 10 l-{(S)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-15 sulfonyl)methylene]azetidine, 1-{(R)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, 1-{ (S)-(4-chlorophenyl) [4-(diethylaminomethyl)-20 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl sulfonyl)methylene]azetidine, 25 1-{ (R)-(4-chlorophenyl) [4-(piperazin-2-one-4-ylmethyl) phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{(S)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl) phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-30 sulfonyl)methylene]azetidine, 1-{(RS)-(4-chlorophenyl)[4-(imidazol-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(imidazol-l-ylmethyl)-35 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, 47 l-{(S)-(4-chlorophenyl)[4-(imidazol-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, (RS)-l-{(4-chlorophenyl)[4-(N,N-5 dimethylcarbamoy1)phenyl]methyl> — 3—[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)—1—{(4-chlorophenyl)[4-(N,N-dimethy1carbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 10 (S)-l-{(4-chlorophenyl)[4-(N,N- dimethylcarbamoyl)phenyl]methyl}—3—[(3,5 — difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4-(N-ethylcarbamoyl)phenyl]methyl) }-3-[ (3,5-15 difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-l-{ (4-chlorophenyl) [4 —(N— ethylcarbamoyl)phenyl]methyl}-3-[ (3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)—1 — { (4-chlorophenyl) [4-(N-20 ethylcarbamoyl)phenyl]methyl}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[ (3,5-difluorophenyl) (methylsulfonyl)methylene]-azetidine, 25 (R)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine, (S)—1—[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-30 azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-dichlorophenyl) (methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(3-methylsulfanylphenyl)(methylsulf onyl ) methylene ] azetidine, 35 l-benzhydryl-3-[(3-methylsulfanylmethyl)phenyl)]-(methylsulfonyl)methylene]azetidine, 48 1-[bis(4-chlorophenyl)methyl]-3-[(3-cyanophenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-carbamoylphenyl)-(methylsulfonyl)methylene]azetidine, 5 1-[bis(4-chlorophenyl)methyl]-3-[(3-methoxyphenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxyphenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl) (3-10 pyrrolidinylphenyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxy-methylphenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{(methylsulfonyl)[3-(N-piperidylcarbamoyl)phenyl]methylene}azetidine, 15 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-trifluoromethylsulfanylphenyl)(methylsulfonyl)-methylene]azetidine, 1-[bis(4-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 20 1-[bis(2-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(3-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-25 [(methylsulfonyl)(phenyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (S)—1—[(4-chlorophenyl) (thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, 30 (RS)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3, 5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-1-[(4-chlorophenyl) (thien-2-yl)methyl]-3-[(3, 5-35 difluorophenyl)(methylsulfonyl)methylene]azetidine, 49 l-benzhydryl-3-[(ethylsulfonyl)(phenyl)methylene]-azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{{3-[N-(4-methylpiperazinyl)carbamoyl]phenyl}(methylsulfonyl)-5 methylene}azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{[3—(2,2— dimethylcarbohydrazido)phenyl](methylsulfonyl)-methylene}azetidine, 1-[bis(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)-10 (methylsulfonyl)methylene]azetidine, 1-[bis(p-tolyl)methyl]-3-[(methylsulfonyl)-(phenyl)methylene]azetidine, l-[ (4-chlorophenyl) (4-hydroxymethylphenyl)methyl]-3-[ (3,5-difluorophenyl) (methylsulfonyl)methylene]-15 azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-methylaminophenyl) (methylsulfonyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]—3—[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 20 (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(2-25 methoxycarbonylthien-5-yl)methylene]azetidine, (RS)-1-[bis(4-chlorophenyl)methyl]-3-hydroxy-3-[(methylsulfonyl)(2-methoxycarbonylthien-5-yl)methyl]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(2-isobutylamino-30 carbonylthien-5-yl)(methylsulfonyl)methylene]azetidine 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3-methoxy-carbonylphenyl)(methylsulfonyl)methyl]azetidin-3-ol, 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(methylsulfonyl) (pyridin-4-yl)methyl]azetidin-3-ol, 35 1-[bis(4-chlorophenyl)methyl]-3-[(RS)- (methylsulfonyl)(pyridin-3-yl)methyl]azetidin-3-ol, 50 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(morpholin-4-yl)propyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-5 ylidene}(methanesulfonyl)methyl)-N-(3-dimethylaminopropyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)benzamide, 10 3-({l-[bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)-N-(2-dimethylamino-l methylethyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(piperidin-1-15 yl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-isobutylbenzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(imidazol-1-20 yl)propyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-dimethylaminoethyl)benzamide, N'-methylhydrazide of 3-({1-[bis(4-chlorophenyl)-25 methyl]azetidin-3-ylidene}(methanesulfonyl)-methyl)benzoic acid, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-(morpholin-4-yl)ethyl)benzamide, 30 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)-N-(1-ethylpyrrolidin 2-ylmethyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2,2- 35 dimethylpropyl)benzamide, 51 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(cyclohexylmethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-5 ylidene}(methanesulfonyl)methyl)-N-(cyclopropylmethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-methylbutyl)benzamide, 10 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-phenylpropyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(tetrahydrofuran-2-15 ylmethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2,2-diphenylethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-20 ylidene}(methanesulfonyl)methyl)-N-(2-ethylbutyl)benzamide, methyl ester of 4-{[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)-benzoylamino]methyl}cyclohexanecarboxylic acid, 25 2-amino-l-{4-[3-({1-[bis(4-chlorophenyl)methyl]- azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazin-l-ylJethanone, tert-butyl ester of (2-{4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-30 phenyl]piperazin-l-yl}-2-oxoethyl)carbamic acid, 1-{4-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl}- 2-(methylamino)ethanone, tert-butyl ester of (2-{4-[3-({1-[bis(4-35 chlorophenyl)methyl]azetidin-3- 52 ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl} 2-oxoethyl)-N-methylcarbamic acid, N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene} (methanesulfonyl)methyl)- 5 phenyl]piperazine-l-carbothioic acid, N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazine-l-carboxylic acid, methyl ester of 4-[3-({1-[bis(4-chlorophenyl)methyl]-10 azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-l-carboxylic acid, 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-isobutylpiperazine, 15 l-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-ethylpiperazine, 4-acetyl-l-[3-({1-[bis(4-chlorophenyl)methyl]azetidin- 3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine, 20 l-{4-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl} 2-dimethylaminoethanone, 1-[3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine, 25 tert-butyl ester of 4-[3-({1-[bis (4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-l-carboxylic acid, 1-[bis(4-methoxycarbonylphenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 30 3-acetoxy-l-[bis(4-methoxycarbonylphenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylsulfonyl)methyl]-azetidine, (RS)-4-[4-((4-chlorophenyl) {3- [ (3,5- difluorophenyl)(methanesulfonyl)methylene]azetidin-1-35 yl}methyl)benzyl]morpholine, 53 4-(4-{3-[(l-benzhydrylazetidin-3-ylidene)(methanesulfonyl) methyl]phenoxy}butyl)morpholine, 4—(4—{3—[(l-benzhydrylazetidin-3-ylidene)(methanesulfonyl )methyl]phenoxy}propyl)morpholine, 5 N- {1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}thien- 2-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide, N- [4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 sulfamoyl)phenyl]acetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methylphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dimethoxyphenylsulfonamide, 15 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3-fluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3.4-dichlorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-20 3-cyanophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 2.5-dimethoxyphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-trifluoromethylphenylsulfonamide, 25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-2 ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-1 ylsulfonamide, N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-30 3,4-difluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-1-methyl-lH-imidazol-4-ylsulfonamide, N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}sulfamoyl)-2-chlorophenyl]acetamide, 35 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-3-ylsulfonamide, 54 N- {1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-fluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8-ylsulfonamide, 5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(phenylmethyl)sulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 3,5-difluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid- 2-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-(3-fluoro-5-pyrrolidin-l-ylphenyl)sulfonamide, 15 N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4-fluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylquinol-8-ylsulfonamide, N- {1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-20 N-methylphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- N-methyl(phenylmethyl)sulfonamide, N- {1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3-sulfamoylphenylsulfonamide, 25 2-benzenesulfonyl-N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}acetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 2-(4-toluene-4-sulfonyl)acetamide, (3-chloro-4-(methylsulfonyl)thiophene-2-carboxy)- 30 {1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]amide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3-(2-phenylethylenesulfonyl)propionamide, N- {1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 4-(methylsulfonyl)benzamide, 35 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-(methanesulfonyl)benzamide, 55 10 15 20 25 30 (5-(methylsulfonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide, (5-methylsulfonyl-3-methyl-4-vinylthiophene- 2-carboxy){1-[bis(4-chlorophenyl)methyl]azetidin- 3-yl}amide, (RS)-N-{1-[(4-chlorophenyl)(pyridin-3-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulfonamide, (RS)-N-{l-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulfonamide, 35 N- 1-[bis(4-chlorophenyl)methyl]azetidin- -3- yi}- N- 6-chloropyrid-2-yl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- -3- yi}- N- 6-ethylpyrid-2-yl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- -3- yi}- N- quinol-6-yl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- -3- yi}- N- quinol-5-yl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- -3- yi}- N- isoquinol-5-yl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- -3- yi}- N- pyrid-3-yl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- •3- yi}- N- pyrid-1-oxide-3-yl)methylsulfonamide, N- 1R,2S,4S)-(bicyclo[2.2.1]hept-2-yl)-N- •{1 -[bis- (4- chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide N- 1R,2R,4S)-(bicyclo[2.2.1]hept-2-yl)-N- {1 - [bis- (4- chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide N- 1-[bis(4-chlorophenyl)methyl]azetidin- 3- yi}- N- 3,5-difluorophenyl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- 3- yi}- N- thiazol-2-yl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- 3- yi}- N- 3-methoxyphenyl)methylsulfonamide, N- 1-[bis(4-chlorophenyl)methyl]azetidin- 3- yi}- N- 3-hydroxyphenyl)methylsulfonamide, 56 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N- (3-(hydroxymethyl)phenyl)methylsulfonamide, ethyl N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(methylsulfonyl)-3-aminobenzoate, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N- (isobutylpiperid-4-yl)methylsulfonamide, N-benzyl-N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amine, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)amine, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-ylmethyl)methylsulfonamide, N-{1-[bis(4-fluorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (RS)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (R)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (S)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3, 5-difluorophenyl)methylsulfonamide, (RS)-N-{l-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (R)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (S)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (RS)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (R)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (S)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)benzylsulfonamide, 57 their optical isomers and their pharmaceutically acceptable salts.

4. The combination as claimed in claim 2, for which the compound of formula (I) is chosen from 5 the following compounds: 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3, 5-difluorophenyl)(methylsulfonyl)methyl]azetidin-3-ol, 3-acetoxy-l-[bis(4-chlorophenyl)methyl]-3-[(RS)- (3,5-difluorophenyl)(methylulphonyl)methyl)methylsulfonyl-10 methylazetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-di fluorophenyl) (methylsulfonyl)methylene]azetidine, their optical isomers and their pharmaceutically acceptable salts. 15

5. The combination as claimed in claim 1, in which the CBl receptor antagonist is SR141716, its hydrates and its pharmaceutically acceptable salts or LY320135 and its pharmaceutically acceptable salts.

6. A pharmaceutical composition comprising ?n a CBl receptor antagonist and sibutramine, its hydrate xrr one of arts pharmaceulicdlly acceptable salts ±n -the pure state or with one or more compatible and pharmacologically acceptable diluents and/or adjuvants and/or optionally in combination with another 25 pharmaceutically compatible and physiologically active product.

7. The pharmaceutical composition as claimed in claim 6, for which the CBl receptor antagonist receptor Qf formula I as defined in claim 2. 30

8. The pharmaceutical composition as claimed in claim 7, for which the compound of formula (I) is chosen from the following compounds: l-benzhydryl-3-[(methylsulfonyl)(phenyl)-methylene]azetidine, 35 l-benzhydryl-3-[(3-methylphenyl)(methylsulfonyl)-methylene]azetidine, intellectual property office of n.z. 0 3 aug 2004 RECEIVCn 58 l-benzhydryl-3-[(3-chlorophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3,5-dichlorophenyl)(methylsulfonyl) methylene]azetidine, 5 l-benzhydryl-3-[(2,5-dichlorophenyl)(methylsulfonyl) methylene]azetidine, l-benzhydryl-3-[(2,3-dichlorophenyl)(methylsulfonyl) methylene]azetidine, l-benzhydryl-3-[(3-fluorophenyl)(methylsulfonyl)-10 methylene]azetidine, l-benzhydryl-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, l-benzhydryl-3-[(3-bromophenyl)(methylsulfonyl)-methylene]azetidine, 15 l-benzhydryl-3-[(3-iodophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl) (3-trifluoro-methoxyphenyl)methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl) (3-trifluoro-20 methylphenyl)methylene]azetidine, l-benzhydryl-3-{[3,5-bis(trifluoromethyl)phenyl]-(methylsulfonyl)methylene}azetidine, l-benzhydryl-3-[(3,5-dibromophenyl)(methylsulfonyl)-methylene]azetidine, 25 l-benzhydryl-3-[(3-methoxycarbonylphenyl)-(methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(3-cyanophenyl)(methylsulfonyl)-methylene]azetidine, l-benzhydryl-3-[(3-carbamoylphenyl)(methylsulfonyl)-30 methylene]azetidine, l-benzhydryl-3-[(methylsulfonyl)(naphth-l-yl)(methyl sulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 35 1-[bis(4-methoxyphenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 59 1-[bis(4-methylphenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (RS)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene l-[(4-methoxyphenyl)(phenyl)methyl)]azetidine, 5 (R)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene] l-[(4-methoxyphenyl)(phenyl)methyl]azetidine, (S)-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene] l-[(4-methoxyphenyl)(phenyl)methyl]azetidine, 1-[bis(4-trifluoromethoxyphenyl)methyl]-3-[(3,5-di-10 fluorophenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-trifluoromethylphenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{[3,5-bis(trifluoromethyl) phenyl] methylsulfonylmethylene }azetidine, 15 (RS)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3 [ (3,5-difluorophenyl) (methylsulfonyl)-methylene]azetidine, (R)-l-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)-20 methylene]azetidine, (S)-1-[(4-chlorophenyl)(2,4-dichlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4-25 (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (R)—1—{(4-chlorophenyl)[4- (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, 30 (S)—1—{ (4-chlorophenyl) [4- (hydroxymethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4- (pyrrolidylmethy1)phenyl]methyl}-3-[(3,5-difluoro-35 phenyl)(methylsulfonyl)methylene]azetidine, 60 (R)—1—{(4-chlorophenyl)[4- (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluoro-phenyl)(methylsulfonyl)methylene]azetidine, (S)—1—{ (4-chlorophenyl) [4-5 (pyrrolidylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 10 l-{(R)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(3,3-dimethylpiperidin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluoro-15 phenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(thiomorpholin-4-20 ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(thiomorpholin-4-ylmthyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 25 l-{(RS)-(4-chlorophenyl)[4-(N-ethyl-N- cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3,5-30 difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{ (S)-(4-chlorophenyl) [4-(N-ethyl-N-cyclohexylaminomethyl)phenyl]methyl}-3-[(3, 5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{{(RS)-(4-chlorophenyl) {4- [ (4-ethoxycarbonyl-35 piperazinyl)methyl]phenyl}methyl}}—3—[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, 61 l-{{(R)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-piperazinyl)methyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{{(S)-(4-chlorophenyl){4-[(4-ethoxycarbonyl-5 piperazinyl)methyl]phenyl}methyl}}-3-[(3, 5- difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}—3—[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 10 l-{(R)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(N-cyclopropyl-N-propylaminomethyl)phenyl]methyl}-3-[(3,5— 15 difluorophenyl)(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(diisopropylaminomethyl ) phenyl] methyl } -3- [ (3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-20 phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-sulfonyl)methylene]azetidine, l-{(S)-(4-chlorophenyl)[4-(diisopropylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)-methylene]azetidine, 25 1-{{(RS)-(4-chlorophenyl){4-[bis(2-methoxyethyl)- aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-{{(R)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-30 (methylsulfonyl)methylene]azetidine, 1-{{(S)-(4-chlorophenyl){4-[bis(2-methoxyethyl)-aminomethyl]phenyl}methyl}}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1-{(RS)-(4-chlorophenyl)[4-[di-n-35 propylaminomethyl)phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 62 l-{(R)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)-methylene]azetidine, 1-{(S)-(4-chlorophenyl)[4-(di-n-propylaminomethyl)-5 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene]azetidine, 10 1-{(R)-(4-chlorophenyl)[4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl) (methylsulfonyl) methylene]azetidine, 1-{ (S)- (4-chlorophenyl) [4-(piperidin-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl-15 sulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(4-methylpiperazin-l-20 ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{ (S)- (4-chlorophenyl) [4-(4-methylpiperazin-l-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 25 l-{(RS)-(4-chlorophenyl)[4-(morpholin-4- ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(R)-(4-chlorophenyl)[4-(morpholin-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)-30 (methylsulfonyl)methylene]azetidine, 1-{ (S)- (4-chlorophenyl) [4-(morpholin-4-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, l-{(RS)-(4-chlorophenyl)[4-(diethylaminomethyl)-35 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, 63 l-{(R)-(4-chlorophenyl)[4-(diethylaminomethyl)-phenyl]methyl}-3-[(3, 5-difluorophenyl) (methylsulfonyl) methylene] azetidine, l-{ (S)- (4-chlorophenyl) [4-(diethylaminomethyl)-5 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{(RS)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methyl sulfonyl)methylene]azetidine, 10 1-{(R)-(4-chlorophenyl)[4-(piperazin-2-one-4-ylmethyl) phenyl]methyl}-3-[(3, 5-difluorophenyl) (methylsulfonyl) methylene] azetidine, l-{(S)-(4-chlorophenyl) [4- (piperazin-2-one-4-ylmethyl) phenyl]methyl}-3-[(3, 5-difluorophenyl) (methy1-15 sulfonyl)methylene]azetidine, l-{ (RS)-(4-chlorophenyl) [4-(imidazol-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{(R)-(4-chlorophenyl)[4-(imidazol-l-ylmethyl)-20 phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, l-{ (S)-(4-chlorophenyl) [4-(imidazol-l-ylmethyl)-phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl) methylene] azetidine, 25 (RS)-l-{(4-chlorophenyl)[4-(N,N- dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-1-{(4-chlorophenyl)[4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-30 difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)—1—{ (4-chlorophenyl) [4-(N,N-dimethylcarbamoyl)phenyl]methyl}-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-l-{(4-chlorophenyl)[4-(N-35 ethylcarbamoyl)phenyl]methyl)}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, 64 (R)-l-{(4-chlorophenyl)[4-(N-ethy1carbamoyl)phenyl]methyl}-3-[ (3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)—1—{ (4-chlorophenyl) [4-(N-5 ethylcarbamoyl)phenyl]methyl}-3-[(3,5- difluorophenyl)(methylsulfonyl)methylene]azetidine, (RS)-l-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine, 10 (R)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine, (S)-1-[(4-carbamoylphenyl)(4-chlorophenyl)methyl]-3-[ (3,5-difluorophenyl) (methylsulfonyl)methylene]-15 azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-dichlorophenyl) (methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(3-methylsulfanylphenyl)(methylsulfonyl) methylene]azetidine, 20 l-benzhydryl-3-[(3-methylsulfanylmethyl)phenyl)]-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-cyanophenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-carbamoylphenyl)-25 (methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-methoxyphenyl)-(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxyphenyl)-(methylsulfonyl)methylene]azetidine, 30 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-pyrrolidinylphenyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3-hydroxy-methylphenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{(methylsulfonyl)[3-(N-35 piperidylcarbamoyl)phenyl]methylene}azetidine, 65 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(3-trifluoromethylsulfanylphenyl)(methylsulfonyl)-methylene]azetidine, 1-[bis(4-fluorophenyl)methyl]-3-[(3,5-difluorophenyl) 5 (methylsulfonyl)methylene]azetidine, 1-[bis(2-fluorophenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 1-[bis(3-fluorophenyl)methyl]-3-[(3,5-difluorophenyl) (methylsulfonyl)methylene]azetidine, 10 (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(methylsulfonyl)(phenyl)methylene]azetidine, (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-15 [(methylsulfonyl)(phenyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (R)-1-[(4-chlorophenyl)(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 20 (S)-1-[ (4-chlorophenyl) (thien-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, l-benzhydryl-3-[(ethylsulfonyl)(phenyl)methylene]-azetidine, 1-[bis(4-chlorophenyl)methyl]-3-{{3-[N-(4-25 methylpiperazinyl)carbamoyl]phenyl}(methylsulfonyl)-methylene Jazetidine, 1-[bis(4-chlorophenyl)methyl]-3-{[3-(2,2-dimethylcarbohydrazido)phenyl](methylsulfonyl)-methylene}azetidine, 30 1-[bis(thien-2-yl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]azetidine, 1- [bis (p-tolyl)methyl]-3-[(methylsulfonyl)-(phenyl)methylene]azetidine, l-[ (4-chlorophenyl) (4-hydroxymethylphenyl)methyl]-3-35 [(3,5-difluorophenyl)(methylsulfonyl)methylene]-azetidine, 66 1-[bis(4-chlorophenyl)methyl]-3-[(3-methylaminophenyl) (methylsulfonyl)methylene]azetidine, (RS)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 5 (R)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, (S)-1-[(4-chlorophenyl)(thiazol-2-yl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(methylsulfonyl)(2-10 methoxycarbonylthien-5-yl)methylene]azetidine, (RS)-1-[bis(4-chlorophenyl)methyl]-3-hydroxy-3-[(methylsulfonyl)(2-methoxycarbonylthien-5-yl)methyl]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(2-isobutylamino-15 carbonylthien-5-yl)(methylsulfonyl)methylene]azetidine 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3-methoxy-carbonylphenyl)(methylsulfonyl)methyl]azetidin-3-ol, 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(methylsulfonyl) (pyridin-4-yl)methyl]azetidin-3-ol, 20 1- [bis(4-chlorophenyl)methyl]-3-[(RS)- (methylsulfonyl)(pyridin-3-yl)methyl]azetidin-3-ol, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(morpholin-4-yl)propyl)benzamide, 25 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene](methanesulfonyl)methyl)-N-(3-dimethylaminopropyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-(pyrrolidin-1-30 yl)ethyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)-N-(2-dimethylamino-l- methylethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-35 ylidene}(methanesulfonyl)methyl)-N-(piperidin-1-yl)benzamide, 67 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-isobutylbenzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(3-(imidazol-1-5 yl)propyl)benzamide, 3- ({1- [bis(4-chlorophenyl)methyl]azetidin-3-ylidene](methanesulfonyl)methyl)-N-(2-dimethylaminoethyl)benzamide, N'-methylhydrazide of 3-({1-[bis(4-chlorophenyl)-10 methyl]azetidin-3-ylidene}(methanesulfonyl)-methyl)benzoic acid, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-(morpholin-4-yl)ethyl)benzamide, 15 3- ({1- [bis(4-chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)-N-(1-ethylpyrrolidin 2-ylmethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2,2- 20 dimethylpropyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(cyclohexylmethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-25 ylidene}(methanesulfonyl)methyl)-N-(cyclopropylmethyl)benzamide, 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-methylbutyl)benzamide, 30 3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2-phenylpropyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(tetrahydrofuran-2 35 ylmethyl)benzamide, 68 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-N-(2,2-diphenylethyl)benzamide, 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-5 ylidene}(methanesulfonyl)methyl)-N-(2-ethylbutyl)benzamide, methyl ester of 4-{[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)-benzoylamino]methyl}cyclohexanecarboxylic acid, 10 2-amino-l-{4-[3-({1-[bis(4-chlorophenyl)methyl]- azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazin-l-yl}ethanone, tert-butyl ester of (2-{4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-15 phenyl]piperazin-l-yl}-2-oxoethyl)carbamic acid, 1-{4-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl} 2-(methylamino)ethanone, tert-butyl ester of (2—{4—[3— ({1—[bis(4— 20 chlorophenyl)methyl]azetidin-3- ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl} 2-oxoethyl)-N-methylcarbamic acid, N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-25 phenyl]piperazine-l-carbothioic acid, N-methylamide of 4-[3-({1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-piperazine-l-carboxylic acid, methyl ester of 4-[3-({1-[bis(4-chlorophenyl)methyl]-30 azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-l-carboxylic acid, 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-isobutylpiperazine, 69 1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]-4-ethylpiperazine, 4-acety1-1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-5 3-ylidene}(methanesulfonyl)methyl)phenyl]piperazine, 1-{4—[3- ({1-[bis(4-chlorophenyl)methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)phenyl]piperazin-l-yl}- 2-dimethylaminoethanone, l-[3-({l-[bis(4-chlorophenyl)methyl]azetidin-3-10 ylidene}(methanesulfonyl)methyl)phenyl]piperazine, tert-butyl ester of 4-[3-({1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylidene}(methanesulfonyl)methyl)-phenyl]piperazine-l-carboxylic acid, 1-[bis(4-methoxycarbonylphenyl)methyl]-3-[(3,5- 15 difluorophenyl)(methylsulfonyl)methylene]azetidine, 3-acetoxy-l-[bis(4-methoxycarbonylphenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylsulfonyl)methyl]-azetidine, (RS)-4-[4-((4-chlorophenyl){3-[(3,5-20 difluorophenyl)(methanesulfonyl)methylene]azetidin-1-yl}methyl)benzyl]morpholine, 4-(4-{3-[(l-benzhydrylazetidin-3-ylidene)(methanesulfonyl) methyl]phenoxy}butyl)morpholine, 4-(4-{3-[(l-benzhydrylazetidin-3-ylidene)(methane-25 sulfonyl)methyl]phenoxy}propyl)morpholine, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}thien- 2-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide, 30 N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-sulfamoyl)phenyl]acetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methylphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-35 3,4-dimethoxyphenylsulfonamide, 70 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-fluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3.4-dichlorophenylsulfonamide, 5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-cyanophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 2.5-dimethoxyphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 3-trifluoromethylphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-2 ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-1 ylsulfonamide, 15 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3.4-difluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 1-methyl-lH-imidazol-4-ylsulfonamide, N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-20 3-yl}sulfamoyl)-2-chlorophenyl]acetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid- 3-ylsulfonamide, N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}- 4-fluorophenylsulfonamide, 25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8-ylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-30 3-yl}(phenylmethyl)sulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3.5-difluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid- 2-ylsulfonamide, 35 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-(3-fluoro-5-pyrrolidin-l-ylphenyl)sulfonamide, 71 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4-fluorophenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylquinol-8-ylsulfonamide, 5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylphenylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl(phenylmethyl)sulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 3-sulfamoylphenylsulfonamide, 2-benzenesulfonyl-N-{1-[bis(4-chlorophenyl)methyl] azetidin-3-ylJacetamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 2-(4-toluene-4-sulfonyl)acetamide, 15 (3-chloro-4-(methylsulfonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]amide, N-{1- [bis (4-chlorophenyl)methyl]azetidin-3-yl}- 3-(2-phenylethylenesulfonyl)propionamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-20 4-(methylsulfonyl)benzamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 4-(methanesulfonyl)benzamide, (5-(methylsulfonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide, 25 (5-methylsulfony1-3-methy1-4-vinylthiophene- 2-carboxy){1-[bis(4-chlorophenyl)methyl]azetidin- 3-yl}amide, (RS)-N-{l-[(4-chlorophenyl)(pyridin-3-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulfonamide, 30 (RS)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl] azetidin-3-yl}-3,5-difluorobenzenesulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(6-chloropyrid-2-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-35 N-(6-ethylpyrid-2-yl)methylsulfonamide, 72 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(quinol-6-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(quinol-5-yl)methylsulfonamide, 5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(isoquinol-5-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 N-(pyrid-l-oxide-3-yl)methylsulfonamide, N-(1R, 2S, 4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-(4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide, N-(1R,2R,4S)-(bicyclo[2.2.1]hept-2-yl)-N-{1-[bis-(4-chlorophenyl)methyl]azetidin-3-yl}methylsulfonamide, 15 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(thiazol-2-yl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-20 N-(3-methoxyphenyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-hydroxyphenyl)methylsulfonamide, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-(hydroxymethyl)phenyl)methylsulfonamide, 25 ethyl N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(methylsulfonyl)-3-aminobenzoate, N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(isobutylpiperid-4-yl)methylsulfonamide, N-benzyl-N-{1-[bis(4-chlorophenyl)methyl]azetidin-30 3-yl}amine, N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)amine, N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)methylsulfonamide, 35 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-ylmethyl)methylsulfonamide, 73 N-{1-[bis(4-fluorophenyl)methyl]azetidin-3-yl}-N- (3,5-difluorophenyl)methylsulfonamide, (RS)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin 3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, 5 (R)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (S)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (RS)-N-{l-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin 10 3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (R)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, (S)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide, 15 (RS)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]- azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide (R)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide (S)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-20 azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3, 5-difluorophenyl)benzylsulfonamide, their optical isomers and their pharmaceutically acceptable salts. 25

9. The pharmaceutical composition as claimed in claim 7, for which the compound of formula (I) is chosen from the following compounds: 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylsulfonyl)methyl]azetidin-3-ol, 30 3-acetoxy-l-[bis(4-chlorophenyl)methyl]-3-[(RS)-(3,5-difluorophenyl)(methylulphonyl)methyl)methylsulfonyl-methyl]azetidine, 1-[bis(4-chlorophenyl)methyl]-3-[(3,5— difluorophenyl)(methylsulfonyl)methylene]azetidine, 35 their optical isomers and their pharmaceutically acceptable salts. 74

10. The pharmaceutical composition as claimed in claim 6, in which the CBl receptor antagonist is SR141716, its hydrates and its pharmaceutically acceptable salts or LY320135 and its 5 pharmaceutically acceptable salts.

11. The pharmaceutical composition as claimed in one of claims 6 to 10 for a use which is simultaneous, separate or spread out over time.

12. The pharmaceutical composition as 10 claimed in one of claim 6 to 11, comprising 0.5 to 10 mg of sibutramine and 0.1 to 200 mg of the CBl receptor antagonist.

13. A combination as defined in claim 1 substantially as herein described with reference to any example thereof.

14. A pharmaceutical composition as defined in claim 6 substantially as herein described with reference to any example thereof. INTIopwXAL PROpERTY OFFICE OF n.z. 0 3 AUG 2004 REGElVPn ST 00028 PATENT COMBINATION OF A CBl RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY AVENTIS PHARMA S.A. ABSTRACT The present invention relates to the combination of a CBl receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity. </div>